Revivifying research on relaxin receptor-targeted therapy for cardiovascular diseases

Xiao-Jun Du^{1

2}

Affiliations

¹ Experimental Cardiology Lab, Baker Heart and Diabetes Institute, Commercial Road, Melbourne, VIC 3004, Australia.
² Faculty of Physiology and Pathophysiology, College of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Yanta District, Xi'an, China.

Editorial

Xiao-Jun Du. Cardiovasc Res. 2025.

. 2025 Jun 12;121(6):836-838.

doi: 10.1093/cvr/cvaf057.

Xiao-Jun Du^{1

2}

¹ Experimental Cardiology Lab, Baker Heart and Diabetes Institute, Commercial Road, Melbourne, VIC 3004, Australia.
² Faculty of Physiology and Pathophysiology, College of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 Yanta West Road, Yanta District, Xi'an, China.

No abstract available

Conflict of interest statement

Conflict of interest: none declared.

A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunction.
Papworth M, Kulkarni S, Antonsson M, Sermadiras I, Hovdal D, Connolly K, Olsson J, Shukla A, Cotton P, Althage M, Paterson J, Martin E, Wolny M, Ferraro F, Sadowska A, Hao W, Larsson N, Backmark A, Marlow T, Perez R, Jermutus L, Omar S, George RT, Gabrielsen A, Pettersen D, Jennbacken K. Papworth M, et al. Cardiovasc Res. 2025 Jun 12;121(6):871-881. doi: 10.1093/cvr/cvaf031. Cardiovasc Res. 2025. PMID: 40037346 Free PMC article.